SHELTON, Conn., Oct. 31, 2016 /PRNewswire/ -- NanoViricides,
Inc. (NYSE MKT: NNVC (the "Company") announced today that it has
entered into an agreement with SUNY Upstate
Medical University for the testing of its nanoviricides®
drug candidates against varicella zoster virus, i.e. the shingles
virus.
The research will be performed in the laboratory of Dr.
Jennifer Moffat and will include
in vitro, ex vivo and possibly in vivo
studies. Dr. Moffat has extensive experience in varicella zoster
virus (VZV) infection and antiviral agent discovery. The goal
of these studies is to help select a clinical drug development
candidate for toxicology and safety evaluation intended for
clinical trials for the treatment of shingles in humans.
VZV is restricted to human tissue and only infects and
replicates in human tissue. The in vitro studies will
evaluate the effectiveness of the Company's nanoviricides antiviral
agents against VZV infection of certain human cells in culture. The
ex vivo studies will evaluate the efficacy of the Company's
nanoviricides to inhibit VZV in human skin organ cultures. Dr.
Moffat has developed the human skin organ culture VZV infection
model for the evaluation of therapeutics. This model is a good
representative model of natural VZV infection in humans as well as
an important model for evaluating antiviral activity, because it
demonstrates behavior similar to the skin lesions caused by VZV in
human patients.
Dr. Moffat is an internationally recognized expert on varicella
zoster virus, and her research has focused on the pathogenesis and
treatment of infection by this virus. The National Institutes of
Health has recognized this VZV model via a contract with Dr.
Moffat's lab for evaluating antiviral compounds against VZV. Dr.
Moffat is the director of two research core facilities at SUNY
Upstate: the Center for Humanized Mouse Models and In vivo
Imaging.
The Company has established a direct relationship with the
Moffat lab, without NIH as an intermediary.
About NanoViricides:
NanoViricides, Inc. (www.nanoviricides.com) is a development stage
company that is creating special purpose nanomaterials for
antiviral therapy. The Company's novel nanoviricide® class of drug
candidates are designed to specifically attack enveloped virus
particles and to dismantle them. The Company is developing drugs
against a number of viral diseases including VZV, oral and genital
Herpes, viral diseases of the eye including EKC and herpes
keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza,
HIV, Hepatitis C, Rabies, Dengue
fever, and Ebola virus, among others.
This press release contains forward-looking statements that
reflect the Company's current expectation regarding future events.
Actual events could differ materially and substantially from those
projected herein and depend on a number of factors. Certain
statements in this release, and other written or oral statements
made by NanoViricides, Inc. are "forward-looking statements" within
the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934. You should not
place undue reliance on forward-looking statements since they
involve known and unknown risks, uncertainties and other factors
which are, in some cases, beyond the Company's control and which
could, and likely will, materially affect actual results, levels of
activity, performance or achievements. The Company assumes no
obligation to publicly update or revise these forward-looking
statements for any reason, or to update the reasons actual results
could differ materially from those anticipated in these
forward-looking statements, even if new information becomes
available in the future. Important factors that could cause actual
results to differ materially from the company's expectations
include, but are not limited to, those factors that are disclosed
under the heading "Risk Factors" and elsewhere in documents filed
by the company from time to time with the United States Securities
and Exchange Commission and other regulatory authorities.
Although it is not possible to predict or identify all such
factors, they may include the following: demonstration and proof of
principle in pre-clinical trials that a nanoviricide is safe and
effective; successful development of our product candidates; our
ability to seek and obtain regulatory approvals, including with
respect to the indications we are seeking; the successful
commercialization of our product candidates; and market acceptance
of our products.
Logo - http://photos.prnewswire.com/prnh/20150107/167444LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/nanoviricides-signs-agreement-with-suny-upstate-medical-center-for-testing-of-its-drug-candidates-for-the-treatment-of-shingles-300353912.html
SOURCE NanoViricides, Inc.